Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
نویسندگان
چکیده
Purpose TNF inhibitors are established treatment for poly-juvenile idiopathic arthritis (pJIA), but there are needs of alternative therapy for refractory patients. Tocilizumab (TCZ) has been widely used for rheumatoid arthritis (RA) in adults, and the effectiveness for systemic JIA has been well-documented. However, the experience on pJIA is limited. We compared the clinical courses of our patients of RA and pJIA to estimate the effectiveness of TCZ.
منابع مشابه
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Introduction TCZ, an IL-6R inhibitor, is effective in systemic and polyarticular juvenile idiopathic arthritis (sjia, pjia). BWadjusted, intravenous dosing regimens (TCZ8 mg/kg Q2W for sjia and Q4W for pjia) were assessed in Japanese phase 3 trials. As shown in Results, BW adjustment led to lower TCZ exposure with lower BW; thus, higher doses were proposed for patients (pts) with BW<30 kg in th...
متن کاملRisk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
Tocilizumab (TCZ) is the first FDA- approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3 cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant cytopenias shortly after initiation of TCZ had a history of macrophage activation syndrome. We raise the possibility that patients with a tendency towards MAS have an increa...
متن کاملInhibition of interleukin 6, a new therapeutic option in rheumatoid arthritis
Tocilizumab (TCZ) is a humanized monoclonal antibody which targets the receptor for IL-6, developed by the Japanese pharmaceutical company Chugai and the Swiss company Roche. In Japan it is already under use for Castleman’s disease, rheumatoid arthritis (RA), and juvenile idiopathic arthritis. The clinical development outside Japan is very extensive and has shown efficacy in possible RA scenari...
متن کامل[Inhibition of interleukin 6, a new therapeutic option in rheumatoid arthritis].
Tocilizumab (TCZ) is a humanized monoclonal antibody which targets the receptor for IL-6, developed by the Japanese pharmaceutical company Chugai and the swiss company Roche. In Japan it is already under use for Castleman's disease, rheumatoid arthritis (RA) and Juvenile Idiopathic Arthritis. The clinical development outside Japan is very extensive and has shown efficacy in possible RA scenario...
متن کاملSafety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
Because of the pathological role of IL-6 in rheumatoid arthritis (RA), tocilizumab (TCZ), a humanized anti-IL-6 receptor monoclonal antibody, was expected to improve inflammation and joint destruction of RA. Indeed, randomized clinical trials demonstrated the clinical efficacy of TCZ as monotherapy or combined with methotrexate (MTX) for RA patients with inadequate responses to disease-modifyin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 10 شماره
صفحات -
تاریخ انتشار 2012